Kankan She

Dr. Kankan She

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
YZYanqin Zhou
Yanqin Zhou
XYXiaona Yang
Xiaona Yang
RLRu Lv
Ru Lv
XLXufeng Lang
Xufeng Lang
YZyao Zhu
yao Zhu
KSKankan She
Kankan She
The accurate prediction of herb–target interactions is essential for the modernization of traditional Chinese medicine (TCM) and the advancement of drug discovery. Nonetheless, the inherent complexity of herbal compositions and diversity of molecular targets render experimental validation both time-consuming and labor-intensive. We propose a graph neural network model, MAMGN-HTI, which integrates metapaths with attention mechanisms. A heterogeneous graph consisting of herbs, efficacies, ingredients, and targets is constructed, where semantic metapaths capture latent relationships among nodes. An attention mechanism is employed to dynamically assign weights, thereby emphasizing the most informative metapaths. In addition, ResGCN and DenseGCN architectures are combined with cross-layer skip connections to improve feature propagation and enable effective feature reuse. Experiments show that MAMGN-HTI outperforms several state-of-the-art methods across multiple metrics, exhibiting superior accuracy, robustness, and generalizability in HTI prediction and candidate drug screening. Validation against literature and databases further confirms the model’s predictive reliability. The model also successfully identified herbs with potential therapeutic effects for hyperthyroidism, including Vinegar-processed Bupleuri Radix (Cu Chaihu), Prunellae Spica (Xiakucao), and Processed Cyperi Rhizoma (Zhi Xiangfu). MAMGN-HTI provides a reliable computational framework and theoretical foundation for applying TCM in hyperthyroidism treatment, providing mechanistic insights while improving research efficiency and resource utilization.

3 November 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
RLRu Lv
Ru Lv
XXXiaoyu Xu
Xiaoyu Xu
YJYulin Ji
Yulin Ji
JWjianxiang wei
jianxiang wei
ZZZuojian Zhou
Zuojian Zhou
KSKankan She
Kankan She
Introduction: Adverse drug reaction (ADR) prediction remains challenging because spontaneous reporting data leave many exposure unit–ADR associations unobserved and provide limited support for candidate prioritization and mechanistic interpretation. Methods: We developed MEG-HHGN, a mechanistic evidence-guided hyperbolic heterogeneous graph neural network. It represents exposure units as combinations of standardized drug names and routes of administration and integrates spontaneous reports with compounds, drug targets, ADR-related targets, and protein–protein interactions. Using 73,530 spontaneous reports collected in Jiangsu Province from 2010 to 2023, we evaluated MEG-HHGN against eight baseline methods through five-fold cross-validation. Results: MEG-HHGN achieved AUC/AP/MCC values of 0.9550/0.9537/0.7917 in known-exposure-unit completion and 0.9090/0.9064/0.6587 in side-information-supported exposure-unit cold-start evaluation. Global scoring of unobserved exposure unit–ADR pairs produced a ranked candidate pool for pharmacovigilance review. Representative cases involving intravenous vinorelbine tartrate–myelosuppression and oral aspirin–proteinuria illustrated PPI-bridged and shared-target pathways, respectively. Discussion: MEG-HHGN integrates route-aware prediction, candidate prioritization, and pathway-based interpretation in a unified framework to support signal triage, mechanistic hypothesis generation, and evidence review in post-marketing pharmacovigilance.